PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]

Lipoprotein (a) [Lp(a)] is independently associated with CVD risk. Evolocumab, a monoclonal antibody (mAb) to proprotein convertase subtilisin/kexin type 9 (PCSK9), decreases Lp(a). The potential mechanisms were assessed. A pooled analysis of Lp(a) and LDL cholesterol (LDL-C) in 3,278 patients from...

Full description

Bibliographic Details
Main Authors: Frederick J. Raal, Robert P. Giugliano, Marc S. Sabatine, Michael J. Koren, Dirk Blom, Nabil G. Seidah, Narimon Honarpour, Armando Lira, Allen Xue, Padmaja Chiruvolu, Simon Jackson, Mei Di, Matthew Peach, Ransi Somaratne, Scott M. Wasserman, Rob Scott, Evan A. Stein
Format: Article
Language:English
Published: Elsevier 2016-06-01
Series:Journal of Lipid Research
Subjects:
lipoprotein (a)
low density lipoprotein cholesterol
low density lipoprotein receptor
proprotein convertase subtilisin/kexin type 9
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520351853

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520351853

Similar Items